Methotrexate on a 21-day cycle for low-risk gestational trophoblastic neoplasia.
To perform an outcome analysis of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with a 5-day intramuscular methotrexate (MTX) regimen on a 21-day cycle. A retrospective review of 31 patients with low-risk GTN treated with a 5-day MTX regimen. A total of 31 patients with low-risk GTN (WHO score < 7) received single-agent MTX at a dose of 0.4 mg/kg daily for 5 days every 21 days (mean number of cycles, 3; 83% remission). The only significant toxicity encountered was grade 2 stomatitis in 8 (26%) patients. A 5-day MTX regimen given every 21 days is convenient, well-tolerated and effective for patients with low-risk GTN.